川芎嗪联合依达拉奉治疗急性脑梗死的疗效观察

目的：观察川芎嗪联合自由基清除剂依达拉奉注射液治疗急性脑梗死的临床疗效。方法：选择发病在48h内的急性脑梗死患者116例,按随机对照双盲法分为治疗组和对照组各58例,对照组在综合支持治疗的基础上给予阿司匹林＋奥扎格雷钠,治疗组在对照组基础上加用川芎嗪＋依达拉奉,两组均以14天为1个疗程。比较两组神经功能缺损评分、临床疗效和不良反应。结果：两组治疗后神经缺损评分（NDS）和日常生活能力（ADL）评分均有明显改善,差异有显著性意义（P〈0.05）;治疗组治疗后神经缺损评分和日常生活能力评分均明显优于对照组,两组比较差异有显著性意义（P〈0.05）;治疗组总有效率为91.4%（53/58）,明显高于对照组的75.9%（41/58）,两组比较差异有显著性意义（χ2=5.10,P〈0.05）;两组治疗期间肝肾功能无明显变化,无颅内出血、局部发疹、全身过敏症、恶心、发热等不良反应发生。结论：川芎嗪联合依达拉奉可以发挥各自优势,起到叠加、协同作用,大大提高疗效,有效改善神经功能和日常生活能力,不良反应少,值得在临床进一步推广应用。

TMP Combined Edaravone Treatment of Acute Cerebral Infarction

Objective： To observe the TMP combined free radical scavenger edaravone injection in treating acute cerebral infarction.Methods： The incidence of acute cerebral infarction in patients within 48h of 116 cases,according to randomized controlled double-blind divided into treatment group and control group 58 cases,the control group on the basis of comprehensive support treatment with aspirin ＋ Ozagrel sodium,the treatment group were based on the use TMP ＋ edaravone were administered for 14d was a course of treatment.Neurological deficit scores were compared,the clinical efficacy and adverse reactions.Results： After treatment,neurological deficit score（NDS） and the activities of daily living（ADL） score were significantly improved,the difference was significant（P0.05）;After treatment,the neurological deficit scores and ADL scores were significantly than the control group,the difference was significant（P0.05）;The total effective rate was 91.4%（53/58）,significantly higher than 75.9%（41/58）,the two groups significant difference（χ2 = 5.10,P0.05）;the two groups during treatment,no significant changes in liver and kidney function,no intracranial hemorrhage,local rash,systemic allergy,nausea,fever and other adverse reactions.Conclusion： TMP combined edaravone can play their respective advantages,play overlapping,synergistic effect,greatly enhance the effect and improve neurological function and activities of daily living,adverse reactions,which should be further application in clinical.